Meanwhile, the pivotal phase III randomized clinical trials including Keynote-054, CheckMate-238, and COMBI-AD have validated the efficacy of adjuvant therapy regimens in resected stage III melanomas, comprising immunotherapy (IT) or targeted therapy (TT) in BRAF-mutant melanomas [12,13,14,15]. Here, BRAF is linked to melanoma.